The Beauty Health Company filed SEC Form 8-K: Leadership Update
$SKIN
Medical/Dental Instruments
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 8, 2024
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices)
(Zip Code)
(800 ) 603-4996
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
The | ||||||||||||||
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Chief Revenue Officer Departure
On October 8, 2024, the Board of Directors (the "Board") of The Beauty Health Company (the "Company") terminated Daniel Watson's employment as Chief Revenue Officer of the Company without cause, effective as of October 14, 2024. Mr. Watson will remain employed with the Company in an advisory role until no later than December 31, 2024. Mr. Watson’s termination is not a result of any disagreement with the Company on any matter relating to the Company’s financial reporting, operations, policies or practices.
The Company intends to enter into a separation agreement with Mr. Watson as soon as practicable in connection with his separation as Chief Revenue Officer of the Company that will document any applicable payments or benefits to be provided to him in respect of such separation. The Company will file an amendment to this Current Report on Form 8-K within four business days after the parties enter into a definitive separation agreement.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: October 15, 2024 | The Beauty Health Company | |||||||
| By: | /s/ Michael Monahan | |||||||
| Name: | Michael Monahan | |||||||
| Title: | Chief Financial Officer | |||||||